Mangalam Drugs And Organics Limited
NSE: MANGALAM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Mangalam Drugs And Organics Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mangalam Drugs & Organics Ltd is a pharmaceutical company specialising in the manufacture of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company is notably recognised for its production of artemisinin-based bulk drugs used in anti-malarial formulations.
Business Model
The company operates as a manufacturer and supplier of bulk drugs and organic/inorganic chemicals to pharmaceutical companies. It leverages its World Health Organisation (WHO) approval to partner with global entities like the Clinton Foundation for essential medicine supply chains.
- Incorporation Year:1977
Growth Outlook
Growth is driven by the company's established position in the anti-malarial drug market and its ongoing associations with international health foundations. Future prospects remain tied to the demand for essential APIs and the company's ability to maintain international quality standards.
Key Risks
- Regulatory Compliance. The company's business model relies heavily on maintaining WHO and other international quality certifications, which are subject to rigorous and periodic audits.
- Concentration Risk. Heavy reliance on specific therapeutic segments like anti-malarials may expose the company to fluctuations in global demand and public health funding.
- Raw Material Price Volatility. As a manufacturer of chemicals and APIs, the company is susceptible to price fluctuations in raw materials and chemical feedstocks.
- Competitive Pressure. The Indian API sector is highly fragmented and competitive, which may exert pressure on profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Mangalam Drugs And Organics Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Mangalam Drugs And Organics LimitedMANGALAM | ₹51 Cr | — | — | — | -6.0% | — | — | -59.2% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
Mangalam Drugs And Organics Limited
NSE: MANGALAM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Mangalam Drugs And Organics Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mangalam Drugs & Organics Ltd is a pharmaceutical company specialising in the manufacture of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company is notably recognised for its production of artemisinin-based bulk drugs used in anti-malarial formulations.
Business Model
The company operates as a manufacturer and supplier of bulk drugs and organic/inorganic chemicals to pharmaceutical companies. It leverages its World Health Organisation (WHO) approval to partner with global entities like the Clinton Foundation for essential medicine supply chains.
- Incorporation Year:1977
Growth Outlook
Growth is driven by the company's established position in the anti-malarial drug market and its ongoing associations with international health foundations. Future prospects remain tied to the demand for essential APIs and the company's ability to maintain international quality standards.
Key Risks
- Regulatory Compliance. The company's business model relies heavily on maintaining WHO and other international quality certifications, which are subject to rigorous and periodic audits.
- Concentration Risk. Heavy reliance on specific therapeutic segments like anti-malarials may expose the company to fluctuations in global demand and public health funding.
- Raw Material Price Volatility. As a manufacturer of chemicals and APIs, the company is susceptible to price fluctuations in raw materials and chemical feedstocks.
- Competitive Pressure. The Indian API sector is highly fragmented and competitive, which may exert pressure on profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Mangalam Drugs And Organics Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026